TTM
$23.1B
YoY change
+8.4%
5Y CAGR
+18.1%
Peak year (FY2025)
$19.9B
Cumulative operating income
$164B
Operating Income history chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: $19.9B
Operating Income growth chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: +8.4%
Operating Income history table for Novo Nordisk (NVO) from 2003 to 2025
| FY2025 | $19.9B | +8.4% | +$1.55B | ||
| FY2024 | $18.4B | +24.0% | +$3.55B | ||
| FY2023 | $14.8B | +44.0% | +$4.53B | ||
| FY2022 | $10.3B | +14.0% | +$1.26B | ||
| FY2021 | $9.02B | +3.9% | +$340M | ||
| FY2020 | $8.68B | +11.5% | +$897M | ||
| FY2019 | $7.78B | +7.7% | +$555M | ||
| FY2018 | $7.22B | -6.8% | -$525M | ||
| FY2017 | $7.75B | +10.4% | +$731M | ||
| FY2016 | $7.02B | -3.3% | -$240M | ||
| FY2015 | $7.26B | +25.4% | +$1.47B | ||
| FY2014 | $5.79B | +0.7% | +$39M | ||
| FY2013 | $5.75B | +12.1% | +$621M | ||
| FY2012 | $5.13B | +26.5% | +$1.08B | ||
| FY2011 | $4.05B | +17.7% | +$611M | ||
| FY2010 | $3.44B | +16.1% | +$478M | ||
| FY2009 | $2.96B | +34.8% | +$765M | ||
| FY2008 | $2.2B | +26.3% | +$458M | ||
| FY2007 | $1.74B | +10.2% | +$162M | ||
| FY2006 | $1.58B | +22.6% | +$290M | ||
| FY2005 | $1.29B | +4.8% | +$59.3M | ||
| FY2004 | $1.23B | +15.9% | +$169M | ||
| FY2003 | $1.06B | — | — | ||
| FY2002 | — | — | — | ||
| FY2001 | — | — | — | ||
| FY2000 | — | — | — | ||
| FY1999 | — | — | — | ||
| FY1998 | — | — | — | ||
| FY1997 | — | — | — | ||
| FY1996 | — | — | — | ||
| FY1995 | — | — | — | ||
| FY1994 | — | — | — | ||
| FY1993 | — | — | — | ||
| FY1992 | — | — | — | ||
| FY1991 | — | — | — | ||
| FY1990 | — | — | — | ||
| FY1989 | — | — | — | ||
| FY1988 | — | — | — | ||
| FY1987 | — | — | — | ||
| FY1986 | — | — | — | ||
| FY1985 | — | — | — |
- FY2025$19.9B+8.4%
- FY2024$18.4B+24.0%
- FY2023$14.8B+44.0%
- FY2022$10.3B+14.0%
- FY2021$9.02B+3.9%
- FY2020$8.68B+11.5%
- FY2019$7.78B+7.7%
- FY2018$7.22B-6.8%
- FY2017$7.75B+10.4%
- FY2016$7.02B-3.3%
- FY2015$7.26B+25.4%
- FY2014$5.79B+0.7%
- FY2013$5.75B+12.1%
- FY2012$5.13B+26.5%
- FY2011$4.05B+17.7%
- FY2010$3.44B+16.1%
- FY2009$2.96B+34.8%
- FY2008$2.2B+26.3%
- FY2007$1.74B+10.2%
- FY2006$1.58B+22.6%
- FY2005$1.29B+4.8%
- FY2004$1.23B+15.9%
- FY2003$1.06B—
- FY2002——
- FY2001——
- FY2000——
- FY1999——
- FY1998——
- FY1997——
- FY1996——
- FY1995——
- FY1994——
- FY1993——
- FY1992——
- FY1991——
- FY1990——
- FY1989——
- FY1988——
- FY1987——
- FY1986——
- FY1985——
Operating Income values are taken from Novo Nordisk's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Operating Income at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's current operating income (TTM) is $23.1B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Novo Nordisk (NVO) operating income totalled 128B DKK – edged down 0.5% year-over-year.
Over 2020–2025 (5 years), Novo Nordisk operating income expanded at a +18.7% compound annual rate, with mixed annual results across the window.
The record annual operating income stands at 128B DKK, reached in 2024; the historical low of 647M DKK was recorded in 1987.
Novo Nordisk Operating Income by Year
Novo Nordisk Operating Income 2025: $19.9B
Novo Nordisk posted operating income of 128B DKK ($19.9B) in 2025, edged down 0.5% below 2024.
Novo Nordisk Operating Income 2024: $18.4B
In 2024, Novo Nordisk reported operating income of 128B DKK ($18.4B), grew 25.1% from 2023. This figure represents the highest annual value in the available history.
Novo Nordisk Operating Income 2023: $14.8B
Novo Nordisk operating income in 2023 was 103B DKK ($14.8B), surged 37.1% from 2022.
Novo Nordisk Operating Income 2022: $10.3B
2022's operating income for Novo Nordisk came in at 74.8B DKK ($10.3B), grew 27.6% from 2021.
Novo Nordisk Operating Income 2021: $9.02B
Novo Nordisk operating income in 2021 was 58.6B DKK ($9.02B).
See more financial history for Novo Nordisk (NVO).
Sector peers by Operating Income
Healthcare peers of Novo Nordisk (NVO), ranked by their latest operating income
| $29.7B | |
| $25.6B | |
| $23.5B | |
| $20.1B | |
| $19B | |
| $10.7B | |
| $8.11B | |
| $8.05B |
- $29.7B
- $25.6B
- $23.5B
- $20.1B
- $10.7B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.23% TTM
- Dividend Profile3.49% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History5 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.